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Summary The presence of human chorionic gonadotropin in large bowel cancers was studied immunohisto-
chemically using an immunoperoxidase technique. HCG-positive tumour cells were present in 42 of 194
adenocarcinomas examined (22.0% of colon cancer and 21.2% of rectal cancers). On histological grading, the
hCG-positive rate tended to rise as the degree of differentiation decreased. HCG was detected more
frequently in cancers invading the total bowel wall (27%) than in those invading the partial wall (17.1%).
Lymph node, liver or peritoneal metastases were present more frequently in hCG-positive tumours than in
hCG-negative tumours. Furthermore, there was an intimate correlation between the presence of hCG-positive
tumour cells and CEA doubling times in nine cases with untreated liver metastasis. The survival rate for
patients with tissue hCG-positive cells was lower than for those with hCG-negative tumours. Thus, the
presence of tissue hCG in colorectal cancers may be a biological marker of prognostic significance.
Some patients with gastrointestinal cancer have been
reported to have high serum concentrations of human chor-
ionic gonadotropin (hCG). This finding suggests that there
may be tumour cells able to produce hCG, a hormone
normally secreted from the placental syncytiotrophoblast.
Several reports have shown that the production of hCG by
tumour cells is associated with a more aggressive behaviour
in gastric and breast cancers (Tormery et al., 1977; Walker,
1978). The presence of hCG in cancer tissues has been
demonstrated in some patients with colorectal cancer by the
immunohistochemical method. According to this report, the
presence of hCG-positive cells was associated with greater
local invasion and the presence of lymph node and liver
metastases (Campo et al., 1987). We have, therefore, studied
the incidence of hCG in colorectal cancers and correlated its
presence with a variety of clinicopathological parameters.
Materials and methods
We investigated tumour materials from 194 patients with
large bowel cancers (109 with colon cancers and 85 with
rectal cancers) who had undergone resection of the malig-
nancies in our department. The tumours were macroscopi-
cally classified by the Borrman classification: 16 as type 1.
138 as type 2, 39 as type 3 and one as type 4. Histologically.
99 tumours were classified as well differentiated adenocarci-
noma, 80 as moderately differentiated adenocarcinoma, 10 as
poorly differentiated adenocarcinoma, three as mucinous
adenocarcinoma and two squamous cell carcinoma. Lymph
node metastasis was found in 101 of the patients (52.1%).
metastasis in 33 (17.0%) and peritoneal metastasis in 17
(8.8%).
The resected cancer lesions were fixed in 10% formalin
overnight and embedded in paraffin. The presence of hCG
was demonstrated in the dewaxed 4 im sections by
Sternberger-Taylor's peroxidase-antiperoxidase technique.
Rabbit antiserum against the f-subunit of hCG was obtained
from Dako Limited, and was used at a dilution of 1/200.
Endogenous peroxidase activity was blocked with 0.5%
periodic acid. The hydrated sections were incubated in
normal swine serum at room temperature for 30min to
reduce non-specific staining. Incubation with rabbit IgG to
human hCG as primary antibody was performed at 4°C for
24h. The bridge antiserum, swine anti-rabbit IgG, was used
by incubation at room temperature for 30min. The peroxi-
dase activity was developed using 3-3'-diaminobenzene tetra-
hydrochloride. Positive and negative controls were included
with each bath of staining. Normal placental tissue was
used as a positive control, and negative control studies were
carried out in the absence of the primary antiserum to hCG.
Serum carcinoembryonic antigen (CEA) concentrations
were determined with the CEA Roche RIA test kit using the
indirect assay. Nine patients with untreated liver metastases
exhibited exponential increases in CEA over a period of at
least three consecutive CEA determinations. We calculated
the individual doubling times of the CEA concentration and
investigated the relationship between the CEA doubling
times and the presence of tissue hCG-positive cells.
Statistical significance was calculated using the x2 test and
Student's t test. The outcomes for different groups of
patients were compared by generalised Wilcoxon test.
Results
HCG-immunoreactive tumour cells were found in 42 of the
194 patients with large bowel cancers: 24 with colon cancer
(22.0%) and 18 with rectal cancer (21.2%). Staining of such
cells in a cancer specimen is shown in Figure 1. HCG-
immunoreactivity is localised in the cytoplasm of tumour
cells. No hCG-positive cells are demonstrated in normal
colorectal mucosa. The Borrmann classification of the
in-tissue hCG-positive patients revealed that there were 26
type 2 patients, 12 type 3, three type 1 and one type 4
patient. However, the positivity rate was higher for types 3
and 4 than for type 2 (Table I). HCG immunoreactivity and
the histological classification of the tumours are compared in
Table II. HCG staining was positive in 10 (10.1%) of 99 well
differentiated adenocarcinomas, in 26 (32.5%) of 80 moder-
ately differentiated adenocarcinomas and in five (50%) of 10
poorly differentiated adenocarcinomas. The hCG-positive
cells of poorly differentiated tumours were large spindle cells,
which has a giant nucleus containing a clear nucleolus and
an intensely chromophilic cytoplasm. In well differentiated
tumours, however, hCG was frequently stained in a granular
pattern in the cytoplasm of cubic adenocytes.
The relationship between the presence of hCG and
invasion by the tumours is shown in Table III. Eighteen
(17.1%) of 105 tumours without serosal invasion were hCG
positive. On the other hand, 24 (27%) of 89 with serosal
involvement were positive (P<0.05). Lymphatic invasion
was observed in 72.2% of 152 hCG-negative patients and
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Figure 2 The survival curves of patients undergoing curative
resection (Kaplan-Meier method).
Figure 1 HCG in a large bowel cancer. HCG immunoreactivity
is noted in the cytoplasma of glandular cells with a diffuse
pattern (immunoperoxidase x 135).
85.7% of hCG-positive patients. Venous invasion was also
frequent in the hCG-positive patients. HCG was positive in
30 (29.7%) of 101 cases with lymph node metastases and in
12 (12.9%) of 93 cases without lymph node metastases.
There was a significant difference in the hCG positive rate
between these two groups (P<0.05).
The Dukes' staging of the lesions revealed that in-tissue
hCG was positive in 11.9% of Dukes' A, 12.0% of Dukes'
B, 9.5% of Dukes' C and 64.1% of Dukes' D lesions (Table
IV). HCG was observed in 19 (57.6%) of 33 cases with liver
metastases and in' 14 (82.4%) of 17 cases with peritoneal
dissection. These incidences were significantly higher than
the incidence in cases with liver and peritoneal metastases
(P<0.01, Table V).
The relationship between in-tissue hCG and the doubling
time of CEA is shown in Table VI. The doubling times of
serum CEA in the hCG-positive cases ranged from 17 to 53
days, with a mean of 38+ 15 days. On the other hand, there
were five hCG-negative patients with recorded CEA
doubling times ranging from 50 to 111 days and a mean of
72+26 days. The CEA doubling time was therefore signifi-
cantly shorter in the hCG-positive cases than in the hCG-
negative patients.
Five-year survival was 84% of 124 patients with hCG-
negative carcinoma which allowed curative resection. How-
ever, prognosis was poor in 11 patients with hCG-positive
Table I HCG immunoreactivity in 194 large bowel
cancers of different macroscopic types
Macroscopic No. of hCG
type cases positive Per cent
Borrmann 1 16 3 18.8
2 138 26 18.8
3 39 12 30.8
4 1 1 100
No significant differences.
Table II Relationship between hCG immunoreactivity in large
bowel cancers and histological classification
No. of hCG
Histological type cases positive Per cent
Well different. adenocarcinoma 99 10 lO.la
Moderately different. adenocarcinoma 80 26 32.5a
Poorly different. adenocarcinoma 10 5 50.0a
Mucinous adenocarcinoma 3 0 0
Squamous cell carcinoma 2 1 50.0
P < 0.01.
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Figure 3 The survival curves of patients undergoing palliative
resection (Kaplan-Meier method).
carcinoma, the 5-year survival rate for this group being 53%
(Figure 2). The difference between these two groups was
statistically significant (P<0.01). Among patients who
underwent palliative resection, the 1-year survival was 53%
and the 2-year survival 40% in hCG-negative patients. On
the other hand, the 1-year survival was 28% for 20 hCG-
positive patients, with no survivors at 2 years (Figure 3).
Discussion
It is now well established that gastrointestinal tumours are
associated with a high incidence of hCG production (Braun-
stein et al., 1973; Goldstein et al., 1974; Ito & Tahara, 1983).
Shousha et al. (1986) claimed that 10 out of 45 patients
with large bowel cancer had hCG-positive tissue. Buckley &
Fox (1979) reported that adenoma showed no hCG staining
on immunohistological examination, while hCG-positive cells
were present in as many as 43% of cancer foci (26 of 60
patients). In our study we have detected the presence of
hCG-immunoreactive cells in 42 of the 194 large bowel
cancers. Many studies have addressed the question of the
origin of hCG-producing tumour cells. HCG is a glycopro-
tein hormone consisting of two polypeptide subunits (alpha
and beta) (Pierce & Parsons, 1981). Fukayama et al. (1987)
reported the distribution of hCG subunits to be unbalanced,
and the subunits may therefore be expressed through inde-
pendent mechanisms. They indicated that P-hCG may be
expressed through epitheliomesenchymal interactions in car-
cinomas. Ito & Tahara (1983) argued that there was no
difference in the frequency of hCG activity in gastric cancer
between early and advanced cancers. In our study, hCG-
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Table III Relationship between hCG immuno-
reactivity in large bowel cancers and local invasion of
bowel wall
Invasion of No. of hCG
bowel wall cases positive Per cent
Partial 105 18 17.1a
Total 89 24 27.0a
ap<0.05. Partial, tumours without serosal invasion;
total, tumours with serosal involvement.
Table IV Relationship between hCG immuno-
reactivity in large bowel cancer and histological stage
No. of hCG
Stage cases positive Per cent
Dukes' A 67 8 11.9a
B 25 3 12.0a
C 63 6 9.5a
D 39 25 64.1a
ap<.0
positive cells were found in 15.8% of Dukes' A tumours.
This finding suggests that cancer cells might acquire an
hCG-producing phenotype at a very early stage of growth.
It has been said that hCG-producing carcinomas carry a
poor prognosis and show a high grade of malignancy.
Tormey et al. (1977) observed that in breast cancer patients
with high serum levels of hCG the response chemotherapy
was poor, and remissions were of short duration. It has been
reported that the incidence of lymph node metastases is high
in breast cancers with hCG-positive tumour cells (Walker,
1978). Ito & Tahara (1983) reported that the rate of
metastasis was high and prognosis was poor in cases of
hCG-producing gastric cancer. It has been claimed that
hCG-positive large bowel cancers show severe local invasion
and high rates of lymph node metastasis (Campo et al.,
1987). In our study, the presence of hCG-positive tumour
cells was associated with aggressive local invasion and the
presence of metatases. In addition, prognosis was poor in
colorectal cancer patients with hCG-immunoreactive cells.
All the patients who underwent palliative resection of hCG-
positive large bowel cancer died within 2 years of the
operation. On the other hand, a 2-year survival rate of 40%
was seen in patients with hCG-negative cancer, and some of
them are alive nearly 4 years after operation. Among the
patients who underwent curative resection, the 5-year survi-
val rate was also significantly lower for hCG-positive than
for hCG-negative patients. The results suggest that hCG-
positive cancers may carry a poor prognosis and indicate a
higher grade of malignancy.
Table V Relationship between hCG immunoreactivity in
large bowel cancers and the presence of lymph node, liver or
peritoneal metastases
No of hCG
cases positive Per cent
Lymph node meta.
positive 101 30 297.7a
negative 93 12 12.9a
Liver meta.
positive 33 19 57.6b
negative 161 23 14.3b
Peritoneal meta.
positive 17 14 82.4b
negative 177 28 15.8b
ap<O S bp<0.01.
Table VI Relationship between the presence of tissue
hCG positive cells and the doubling times of serum
CEA
Primary CEA
carcinoma doubling time Mean+s.d.
hCG-positive 17- 53 days 38+ 15 daysa
hCG-negative 50- 111 days 72+26 daysa
ap<0.0.
There was a close correlation between survival and CEA
doubling times for untreated liver metastasis. CEA doubling
line has been claimed to be a good index of tumour growth
rate (Stabb et al., 1982). In our study, we found that the
CEA doubling times in hCG-positive large bowel cancers
were significantly shorter than those in hCG-negative
cancers, suggesting that hCG-positive carcinomas have
higher proliferative activity and higher growth rates.
Why hCG-producing cancers are of high malignancy grade
and carry a poor prognosis is a very interesting question.
Several studies have indicated that hCG changes the cell-
mediated and humoral immune response to the stimulus of
cancer antigens (Contractor & Davies, 1973; Fabris et al.,
1977; Strelkauskas et al., 1975). McManus et al. (1976)
suggested that the presence of hCG on the tumour surface
would suppress the action of the patient's T-cells, thereby
favouring high proliferative activity and local invasions. It is,
however, difficult to support the theory that there are
individual variations in the ability of cells to produce hCG,
and thus that a small amount of hCG changes immunologi-
cal competence. In our study, we have confirmed that
prognosis is poor in hCG-producing colorectal cancer. We
conclude that the presence of hCG-positive tumour cells
reflects the potential malignant behaviour of colorectal
cancers.
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